Targeting `Undruggable' Cancer Proteins with Irreversible Small Molecule Inhibitors: Her3 and KRas
With the lighting speed revolution of technologies in chemistry and biology, increasing number of proteins which eluded scientists' efforts to block them before and were labeled as `undruggable', were successfully targeted with small molecule inhibitors. During the past five years, I have...
Main Author: | Xie, Ting |
---|---|
Other Authors: | Gray, Nathanael Schiander |
Language: | en_US |
Published: |
Harvard University
2014
|
Subjects: | |
Online Access: | http://dissertations.umi.com/gsas.harvard:11384 http://nrs.harvard.edu/urn-3:HUL.InstRepos:12274197 |
Similar Items
-
Drugging the Undruggable: Advances on RAS Targeting in Cancer
by: Miriam Molina-Arcas, et al.
Published: (2021-06-01) -
KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01) -
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01) -
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
by: Josef Gillson, et al.
Published: (2020-05-01) -
The development of potential targets in the treatment of non-small cell lung cancer
by: Zhang Jimin, et al.
Published: (2016-01-01)